Use of Antihypertensive Medications and Survival of Breast, Colorectal, Lung, or Stomach Cancer.

Influence of antihypertensive medications on cancer survival is inconclusive. Using time-dependent Cox regression models, we examined associations of common antihypertensive medications with overall survival (OS) and disease-specific survival (DSS) with comprehensive adjustment for potential confounding factors. Participants were from the Shanghai Women's Health Study (SWHS; 1996-2000) and Shanghai Men's Health Study (SMHS; 2002-2006) in Shanghai, China. Included were 2,891 incident breast, colorectal, lung, and stomach cancer cases. Medication use was extracted from electronic medical records. Median 3.4 year post-diagnosis follow-up (interquartile range=1.0-6.3) found better outcomes among users of angiotensin II receptor blockers with colorectal cancer (OS: adjusted HR=0.62, 95%CI: 0.44, 0.86; DSS: adjusted HR=0.61, 95%CI: 0.43, 0.87) and stomach cancer (OS: adjusted HR=0.62, 95%CI: 0.41, 94; DSS: adjusted HR=0.63, 95%CI: 0.41, 98) and among users of beta-adrenergic receptor blockers with colorectal cancer (OS: adjusted HR=0.50, 95%CI: 0.35, 0.72; DSS: adjusted HR=0.50, 95%CI: 0.34, 0.73). Better survival was also found for calcium channel blockers (DSS: adjusted HR=0.67, 95%CI: 0.47, 97) and diuretics (OS: adjusted HR=0.66, 95%CI: 0.45, 96; DSS: adjusted HR=0.57, 95%CI: 0.38, 85) with stomach cancer. Our findings suggest angiotensin II receptor blockers, beta-adrenergic receptor blockers and calcium channel blockers may be associated with improved survival outcomes of gastrointestinal cancers.

[1]  Xi Chen,et al.  Retrospective clinical study of renin-angiotensin system blockers in lung cancer patients with hypertension , 2019, PeerJ.

[2]  X. Shu,et al.  Diabetes Medication Use in Association with Survival among Patients of Breast, Colorectal, Lung, or Gastric Cancer , 2018, Cancer research and treatment : official journal of Korean Cancer Association.

[3]  Shu-Dong Zhang,et al.  Post-diagnostic calcium channel blocker use and breast cancer mortality: a population-based cohort study. , 2018, Epidemiology.

[4]  C. Cardwell,et al.  Angiotensin receptor blocker use and gastro‐oesophageal cancer survival: a population‐based cohort study , 2018, Alimentary pharmacology & therapeutics.

[5]  H. Brenner,et al.  Immortal time bias in pharmacoepidemiological studies on cancer patient survival: empirical illustration for beta-blocker use in four cancers with different prognosis , 2017, European Journal of Epidemiology.

[6]  W. Barlow,et al.  Use of Antihypertensive Medications and Risk of Adverse Breast Cancer Outcomes in a SEER–Medicare Population , 2017, Cancer Epidemiology, Biomarkers & Prevention.

[7]  C. Shapiro,et al.  Cardiotoxic effects of anthracycline-based therapy: what is the evidence and what are the potential harms? , 2017, The Lancet. Oncology.

[8]  H. Brenner,et al.  Pre- and post-diagnostic β-blocker use and lung cancer survival: A population-based cohort study , 2017, Scientific Reports.

[9]  L. Kiemeney,et al.  History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium , 2017, Cancer Causes & Control.

[10]  Weimin Cai,et al.  Do renin–angiotensin system inhibitors influence the recurrence, metastasis, and survival in cancer patients? , 2017, Medicine.

[11]  Kyoungjune Pak,et al.  Is Beta-Blocker Use Beneficial in Breast Cancer? A Meta-Analysis , 2017, Oncology.

[12]  B. Bryan,et al.  Use of non-selective β-blockers is associated with decreased tumor proliferative indices in early stage breast cancer , 2016, Oncotarget.

[13]  Mats Lambe,et al.  Propranolol and survival from breast cancer: a pooled analysis of European breast cancer cohorts , 2016, Breast Cancer Research.

[14]  P. Douglas,et al.  Cardiovascular Disease Among Survivors of Adult-Onset Cancer: A Community-Based Retrospective Cohort Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Hong Sun,et al.  No Association Between Calcium Channel Blockers and Survival in Patients with Cancer: A Systematic Review and Meta-analysis. , 2016, Asian Pacific journal of cancer prevention : APJCP.

[16]  Sara Gandini,et al.  Use of beta‐blockers, angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers and breast cancer survival: Systematic review and meta‐analysis , 2016, International journal of cancer.

[17]  Wei Chen,et al.  Impact of Angiotensin I-converting Enzyme Inhibitors and Angiotensin II Type-1 Receptor Blockers on Survival of Patients with NSCLC , 2016, Scientific Reports.

[18]  C. Hollenbeak,et al.  β-Blockers Reduce Breast Cancer Recurrence and Breast Cancer Death: A Meta-Analysis. , 2015, Clinical breast cancer.

[19]  S. Matsusaka,et al.  Angiotensin II type-1 receptor blockers enhance the effects of bevacizumab-based chemotherapy in metastatic colorectal cancer patients. , 2015, Molecular and clinical oncology.

[20]  X. Shu,et al.  Cohort Profile: The Shanghai Men's Health Study. , 2015, International journal of epidemiology.

[21]  D. Gomez,et al.  Incidental receipt of cardiac medications and survival outcomes among patients with stage III non-small-cell lung cancer after definitive radiotherapy. , 2015, Clinical lung cancer.

[22]  J. Hanley,et al.  Avoiding blunders involving 'immortal time'. , 2014, International journal of epidemiology.

[23]  H. Brenner,et al.  Stage‐specific associations between beta blocker use and prognosis after colorectal cancer , 2014, Cancer.

[24]  L. Murray,et al.  Drugs affecting the renin-angiotensin system and survival from cancer: a population based study of breast, colorectal and prostate cancer patient cohorts , 2014, BMC Medicine.

[25]  G. Minuk,et al.  Antihypertensive medications and survival in patients with cancer: a population-based retrospective cohort study. , 2013, Cancer epidemiology.

[26]  D. Powe,et al.  Beta-blocker usage and breast cancer survival: a nested case-control study within a UK clinical practice research datalink cohort. , 2013, International journal of epidemiology.

[27]  N. Weiss,et al.  Threats to validity of nonrandomized studies of postdiagnosis exposures on cancer recurrence and survival. , 2013, Journal of the National Cancer Institute.

[28]  Jose M Garcia,et al.  Exposure to ACEI/ARB and β-Blockers Is Associated with Improved Survival and Decreased Tumor Progression and Hospitalizations in Patients with Advanced Colon Cancer. , 2013, Translational oncology.

[29]  G. Hortobagyi,et al.  Use of ACE Inhibitors and Angiotensin Receptor Blockers and Primary Breast Cancer Outcomes , 2013, Journal of Cancer.

[30]  T. Ahern,et al.  Use of β-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and risk of breast cancer recurrence: a Danish nationwide prospective cohort study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  S. Hankinson,et al.  Beta blockers and angiotensin-converting enzyme inhibitors’ purported benefit on breast cancer survival may be explained by aspirin use , 2013, Breast Cancer Research and Treatment.

[32]  Yi Ji,et al.  β-blockers: a novel class of antitumor agents , 2012, OncoTargets and therapy.

[33]  S. Bojesen,et al.  Statin use and reduced cancer-related mortality. , 2012, The New England journal of medicine.

[34]  C. Hughes,et al.  Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in cancer progression and survival: a systematic review , 2012, Cancer Causes & Control.

[35]  Steven W. Cole,et al.  Molecular Pathways: Beta-Adrenergic Signaling in Cancer , 2011, Clinical Cancer Research.

[36]  K. Bennett,et al.  Beta blockers and breast cancer mortality: a population- based study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  J. McGrath,et al.  Previously unsuspected widespread cellular and tissue distribution of β-adrenoceptors and its relevance to drug action. , 2011, Trends in pharmacological sciences.

[38]  R. Hannan,et al.  The renin–angiotensin system and cancer: old dog, new tricks , 2010, Nature Reviews Cancer.

[39]  M. Perrone,et al.  Upregulation of β3-Adrenergic Receptor mRNA in Human Colon Cancer: A Preliminary Study , 2008, Oncology.

[40]  Samy Suissa,et al.  Immortal time bias in pharmaco-epidemiology. , 2008, American journal of epidemiology.

[41]  S. Atlas.  The Renin-Angiotensin Aldosterone System: Pathophysiological Role and Pharmacologic Inhibition , 2007, Journal of managed care pharmacy : JMCP.

[42]  J. LeLorier,et al.  Application of lag‐time into exposure definitions to control for protopathic bias , 2007, Pharmacoepidemiology and drug safety.

[43]  S. Sheps,et al.  Specific comorbidity risk adjustment was a better predictor of 5-year acute myocardial infarction mortality than general methods. , 2006, Journal of clinical epidemiology.

[44]  G. Becker,et al.  Malignant ascites: systematic review and guideline for treatment. , 2006, European journal of cancer.

[45]  N. Rothman,et al.  The Shanghai Women's Health Study: rationale, study design, and baseline characteristics. , 2005, American journal of epidemiology.

[46]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[47]  P. Whelton,et al.  Hypertension , 1942, Nature Reviews Disease Primers.

[48]  C. Choi,et al.  The effect of angiotensin system inhibitors (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) on cancer recurrence and survival: a meta-analysis , 2017, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[49]  A. Salahudeen,et al.  Hypertension in cancer patients. , 2011, Texas Heart Institute journal.

[50]  E L Korn,et al.  Time-to-event analysis of longitudinal follow-up of a survey: choice of the time-scale. , 1997, American journal of epidemiology.